BioCentury
ARTICLE | Company News

Spark gives Roche beachhead in gene therapy

February 25, 2019 7:11 AM UTC

Roche (SIX:ROG; OTCQX:RHHBY) will acquire Spark Therapeutics Inc. (NASDAQ:ONCE) for $4.8 billion in a deal that marks the Swiss pharma's first major move into gene therapy.

The deal announced early Monday was the first major acquisition since James Sabry became global head of pharma partnering (see “Roche’s Partnering Priority”). ...

BCIQ Company Profiles

Roche

Spark Therapeutics Inc.